Cancer vaccines in development

Cancer vaccines in development

Company Product Description Indication Status
Avax/Pro Vaccine/Australian Vaccine Tech M-Vax Autologous haptenized tumor cell vaccine Stage III and IV melanoma Compassionate use in France, Spain and Belgium; Ph I/II in U.S. (start Ph III 1H06)
Biomira/ Merck KGaA Stimuvax (BLP25) liposome vaccine Liposomal vaccine containing a synthetic 25 amino acid peptide sequence from MUC-1 Non-small cell lung cancer (NSCLC) Ph IIb compl (start Ph III in mid-06)
Intracel OncoVax Autologous tumor cells combined with bacille Calmette-Guerin (BCG) Stage II colon cancer Start Ph III

Read the full 893 word article

How to gain access

Continue reading with a
two-week free trial.